Bellicum pharmaceuticals to participate in three healthcare investor conferences during september

Houston, aug. 28, 2019 (globe newswire) -- bellicum pharmaceuticals, inc. (nasdaq:blcm), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that senior management will participate in three upcoming healthcare investor conferences.

BLCM Ratings Summary

BLCM Quant Ranking